AUTHORS
Christine Gruessner, MD MPH, Christopher Pleyer, MD, MBA2, Constance Yuan, MD, PhD3, Hao-Wei Wang, MD, PhD4, Dana Delgado Colon, MD5, Chantal Saberian, MD6, Farzeen Syed, DO7, Ingrid Frey8, Boeui Kang9, Jeanine Superata, NP10, Laura Samples, MD11, Clare Sun, MD12, Adrian Wiestner, MD, PhD13
AFFILIATIONS
1 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
2 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
3 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
4 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
5 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
6 National Cancer Institute, NIH, Bethesda, Maryland, United States
7 National Cancer Institute, NIH, Bethesda, Maryland, United States
8 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
9 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
10 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
11 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
12 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
13 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
ABSTRACT
Background: Fixed-duration venetoclax-based therapy induces deep remissions in treatment-naïve (TN) and relapsed/refractory (RR) CLL. Efficacy and durability of response of venetoclax in patients progressing on Bruton Tyrosine Kinase inhibitors (BTKi) remains less well characterized. We report efficacy and measurable residual disease (MRD) outcomes from a prospective single-center study of fixed-duration venetoclax-based therapy in TN and RR CLL at 4 years of median follow-up.
Methods: The clinical study was registered as NCT03986034 at clinicaltrials.gov, and conducted compliant with the Declaration of Helsinki. Following a standard 5-week ramp-up, patients continued treatment with their home provider and received venetoclax for 12 cycles (28 days/cycle) in the TN cohort and 24 cycles in the RR cohort. Most RR, and all TN patients received anti-CD20 therapy for 6 months beginning after the ramp-up; obinutuzumab in TN, rituximab or obinutuzumab in RR patients. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods and compared by log-rank testing. Minimal residual disease (MRD) was measured annually by peripheral blood flow cytometry with a sensitivity of 2x10-5; undetectable MRD (uMRD) was defined as absence of detectable CLL cells. Duration of uMRD was analyzed from EOT to first detectable MRD using Cox proportional-hazards regression, with censoring at the latest evaluable MRD assessment.
Results:
50 patients with active disease were enrolled, 24 (48%) were TN, and 26 (52%) had RR CLL. Among RR patients, 24 (92%) had been treated with a BTKi and 21 (88%) discontinued the BTKi due to PD with BTK and/or PLCG2 resistance mutations detected in 13 patients. Patients progressing on a BTKi stopped treatment the day before initiating venetoclax, overlap between agents was not permissible. With a median follow-up of 47.8 months (range, 12.0–77.8 months), 41.9 months in TN, 59.8 months in RR, 16 PFS events (12 progression, 4 deaths) had occurred. Eight patients had progressive CLL and 4 patients, all previously treated with BTKi had Richter Transformation to DLBCL. Median PFS was 67.5 months overall, was not reached in TN patients, and was 39.8 months in RR patients. Estimated overall PFS at 4 years was 58.6%; in RR patients estimated PFS at 4 years was 45.4%. OS at 3 years for the entire cohort was estimated at 88.1%. Estimated 4-year OS of RR patients was 83.9%.
uMRD at EOT was achieved in 20/21 (95.2%) evaluable TN patients and 16/19 (84.2%) evaluable RR patients (p=0.331). Despite similarly high EOT uMRD rates, the durability of uMRD diverged following treatment discontinuation. One year after EOT, uMRD was maintained in 19/23 (82.6%) TN patients compared with 8/16 (50.0%) RR patients (p=0.041). At three years after EOT, corresponding rates were 6/11 (54.5%) and 2/8 (25.0%) (p=0.352). Of 36 patients achieving uMRD at EOT, 17 subsequently lost uMRD. RR patients experienced significantly shorter duration of uMRD than TN patients (hazard ratio 3.33, 95% confidence interval 1.20–9.23; P=0.021).
Tolerability was consistent with prior reports, laboratory TLS occurred in 2 patients. Disease flares after discontinuation of BTKis occurred in 5 (21%) RR patients during the first 2 weeks of venetoclax ramp-up. Common reasons for venetoclax interruptions or dose reductions were neutropenia and thrombocytopenia.
Conclusions:
Fixed-duration venetoclax-based therapy provides durable long-term clinical benefit in both TN and RR CLL, with superior PFS observed in TN patients. EOT uMRD rates were high in both cohorts. However, TN patients maintained uMRD significantly longer following treatment discontinuation than RR patients. Nevertheless, almost half of RR patients, most having progressed on prior BTKi therapy, were estimated to be alive and progression free at 4 years. Venetoclax based treatment for patients progressing on BTKi is effective and can provide years of treatment-free remission.
DISCLOSURES
Christine Gruessner, MD MPH: No relevant conflicts of interest to declare.